Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology

被引：5

作者：

Shah, Nina ^{[1
,5
]}

Mustafa, S. Shahzad ^{[2
,3
]}

Vinh, Donald C. ^{[4
]}

机构：

[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94115 USA

[2] Rochester Reg Hlth, Rochester, NY USA

[3] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY USA

[4] McGill Univ, Hlth Ctr, Dept Med, Montreal, PQ, Canada

[5] Univ Calif San Francisco, 400 Parnassus Ave, 4th Fl, San Francisco, CA 94143 USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 181卷

关键词：

Hematological malignancy; Secondary immunodeficiency; Immunoglobulin; Vaccination; Diagnosis; Immunoglobulin replacement therapy; CHRONIC LYMPHOCYTIC-LEUKEMIA; IMMUNOGLOBULIN REPLACEMENT THERAPY; COMMON VARIABLE IMMUNODEFICIENCY; INTRAVENOUS IMMUNE GLOBULIN; DISEASES WORKING PARTY; ANTIBODY DEFICIENCY; MULTIPLE-MYELOMA; INFECTIOUS COMPLICATIONS; HUMORAL IMMUNITY; RANDOMIZED-TRIAL;

D O I：

10.1016/j.critrevonc.2022.103896

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Secondary immunodeficiency (SID) in patients with B-cell hematological malignancies is a common condition that presents with recurrent infection. SID is due to both the inherent immune defects due to the malignancy, as well as secondary to cancer therapies, many of which have B-cell depleting properties. The early diagnosis of SID and the optimization of intervention strategies are key to delivering the most effective cancer treatments and reducing infection-related morbidity and mortality. This review discusses current practice, recommendations, and challenges for SID diagnosis, based on the evaluation of clinical history and laboratory assessments, and the effectiveness of specific vaccines and immunoglobulin replacement therapy in reducing the frequency and recurrence of infections in patients with SID, and the healthcare system-associated costs.

引用

页数：10

共 112 条

[51]

Kobayashi M, 2022, MMWR-MORBID MORTAL W, V71, P109, DOI 10.15585/mmwr.mm7104a1

[52] B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells [J].

Kochenderfer, James N. ;

Dudley, Mark E. ;

Feldman, Steven A. ;

Wilson, Wyndham H. ;

Spaner, David E. ;

Maric, Irina ;

Stetler-Stevenson, Maryalice ;

Phan, Giao Q. ;

Hughes, Marybeth S. ;

Sherry, Richard M. ;

Yang, James C. ;

Kammula, Udai S. ;

Devillier, Laura ;

Carpenter, Robert ;

Nathan, Debbie-Ann N. ;

Morgan, Richard A. ;

Laurencot, Carolyn ;

Rosenberg, Steven A. .

BLOOD, 2012, 119 (12) :2709-2720

[53] Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 [J].

Kochenderfer, James N. ;

Wilson, Wyndham H. ;

Janik, John E. ;

Dudley, Mark E. ;

Stetler-Stevenson, Maryalice ;

Feldman, Steven A. ;

Maric, Irina ;

Raffeld, Mark ;

Nathan, Debbie-Ann N. ;

Lanier, Brock J. ;

Morgan, Richard A. ;

Rosenberg, Steven A. .

BLOOD, 2010, 116 (20) :4099-4102

[54] Potential Drug-Drug Interactions with Antimicrobials in Hospitalized Patients: A Multicenter Point-Prevalence Study [J].

Kuscu, Ferit ;

Ulu, Astihan ;

Inal, Ayse S. ;

Suntur, Bedia M. ;

Aydemir, Hande ;

Gul, Serdar ;

Ecemis, Kenan ;

Komur, Suheyta ;

Kurtaran, Behice ;

Kuscu, Oztem Ozkan ;

Tasova, Yesim .

MEDICAL SCIENCE MONITOR, 2018, 24 :4240-4247

[55] A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia [J].

Lachance, S. ;

Christofides, A. L. ;

Lee, J. K. ;

Sehn, L. H. ;

Ritchie, B. C. ;

Shustik, C. ;

Stewart, D. A. ;

Toze, C. L. ;

Haddad, E. ;

Vinh, D. C. .

CURRENT ONCOLOGY, 2016, 23 (01) :42-51

[56] Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections [J].

Lahue, Betsy J. ;

Mallick, Rajiv ;

Zhang, Xiang ;

Heidt, Julien ;

Song, Yufei ;

Koenig, Andrew S. ;

Espinoza, Gabriela .

IMMUNOTHERAPY, 2022, 14 (15) :1245-1261

[57] OBSERVATIONS ON THE ANTIBODY CONTENT OF THE BLOOD IN PATIENTS WITH MULTIPLE MYELOMA [J].

LAWSON, HA ;

STUART, CA ;

PAULL, AM ;

PHILLIPS, AM ;

PHILLIPS, RW .

NEW ENGLAND JOURNAL OF MEDICINE, 1955, 252 (01) :14-18

[58] Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study [J].

Legendre, Paul ;

Chahwan, Doumit ;

Marjanovic, Zora ;

Vignon, Marguerite ;

Hermine, Olivier ;

Lortholary, Olivier ;

Morelle, Guillaume ;

Darrodes, Marie ;

Kahn, Jean-Emmanuel ;

Ouzegdouh, Maya ;

Chaibi, Pascal ;

Montestruc, Francois ;

Caumont-Prim, Aurore ;

Le Jouan, Melisande ;

Hassani, Yasmine ;

Godeau, Bertrand ;

Durand-Zaleski, Isabelle ;

Mouthon, Luc .

CLINICAL IMMUNOLOGY, 2020, 215

[59] Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network [J].

Ludwig, Heinz ;

Boccadoro, Mario ;

Moreau, Philippe ;

San-Miguel, Jesus ;

Cavo, Michele ;

Pawlyn, Charlotte ;

Zweegman, Sonja ;

Facon, Thierry ;

Driessen, Christoph ;

Hajek, Roman ;

Dimopoulos, Melitios A. ;

Gay, Francesca ;

Avet-Loiseau, Herve ;

Terpos, Evangelos ;

Zojer, Niklas ;

Mohty, Mohamad ;

Mateos, Maria-Victoria ;

Einsele, Hermann ;

Delforge, Michel ;

Caers, Jo ;

Weisel, Katja ;

Jackson, Graham ;

Garderet, Laurent ;

Engelhardt, Monika ;

van de Donk, Niels ;

Leleu, Xavier ;

Goldschmidt, Hartmut ;

Beksac, Meral ;

Nijhof, Inger ;

Abildgaard, Niels ;

Bringhen, Sara ;

Sonneveld, Pieter .

LEUKEMIA, 2021, 35 (01) :31-44

[60] Infections in secondary immunodeficiency patients treated with Privigen(R) or Hizentra(R): a retrospective US administrative claims study in patients with hematological malignancies [J].

Mallick, Rajiv ;

Divino, Victoria ;

Smith, B. Douglas ;

Jolles, Stephen ;

DeKoven, Mitchell ;

Vinh, Donald C. .

LEUKEMIA & LYMPHOMA, 2021, 62 (14) :3463-3473

← 1 2 3 4 5 6 7 8 9 10 →